CRXT - Clarus Therapeutics GAAP EPS of -$0.61 misses by $0.15 revenue of $4.01M misses by $0.94M May, 16 2022 04:11 PM Clarus Therapeutics Holdings Inc. Clarus Therapeutics press release (NASDAQ:CRXT): Q1 GAAP EPS of -$0.61 misses by $0.15. Revenue of $4.01M (+72.1% Y/Y) misses by $0.94M. For further details see: Clarus Therapeutics GAAP EPS of -$0.61 misses by $0.15, revenue of $4.01M misses by $0.94M